Baryons and Skyrmions in QCD with Quarks in Higher Representations

We study the baryonic sector of QCD with quarks in the two index symmetric or antisymmetric representation. The minimal gauge invariant state that carries baryon number cannot be identified with the Skyrmion of the low energy chiral effective Lagrangian. Mass, statistics and baryon number do not match. We carefully investigate the properties of the minimal baryon in the large N limit and we find that it is unstable under formation of bound states with higher baryonic number. These states match exactly with the properties of the Skyrmion of the effective Lagrangian.Comment: 23 pages, 13 figures. v2: minor changes. v3: corrected a mistake and some typos. v4: modifyed the part about the stability of the Skyrmio

Evidence of slippage breakdown for a superhydrophobic microchannel

© 2014 AIP Publishing LLC.A full characterization of the water flow past a silicon superhydrophobic surface with longitudinal micro-grooves enclosed in a microfluidic device is presented. Fluorescence microscopy images of the flow seeded with fluorescent passive tracers were digitally processed to measure both the velocity field and the position and shape of the liquid-air interfaces at the superhydrophobic surface. The simultaneous access to the meniscus and velocity profiles allows us to put under a strict test the no-shear boundary condition at the liquid-air interface. Surprisingly, our measurements show that air pockets in the surface cavities can sustain non-zero interfacial shear stresses, thereby hampering the friction reduction capabilities of the surface. The effects of the meniscus position and shape as well as of the liquid-air interfacial friction on the surface performances are separately assessed and quantified

Interplay of the volume and surface plasmons in the electron energy loss spectra of C60_{60}

The results of a joint experimental and theoretical investigation of the C60 collective excitations in the process of inelastic scattering of electrons are presented. The shape of the electron energy loss spectrum is observed to vary when the scattering angle increases. This variation arising due to the electron diffraction of the fullerene shell is described by a new theoretical model which treats the fullerene as a spherical shell of a finite width and accounts for the two modes of the surface plasmon and for the volume plasmon as well. It is shown that at small angles, the inelastic scattering cross section is determined mostly by the symmetric mode of the surface plasmon, while at larger angles, the contributions of the antisymmetric surface plasmon and the volume plasmon become prominent.Comment: 11 pages, 3 figure

Strings Inside Walls in N=1 Super Yang-Mills

We conjecture the existence of strings bounded inside walls in SU$(n)$ $\N=1$ Super Yang-Mills theory. These strings carry $\Z_{[k,n]}$ quantum number, where $[k,n]$ is the greatest common divisor between $k$, the charge of the wall, and $n$. We provide field-theoretical arguments and string-theoretical evidences, both from MQCD and from gauge-gravity correspondence. We interpret this result from the point of view of the low-energy effective action living on the $k$-wall.Comment: 25 pp. Major changes. In particular, following the recent work arXiv:0807.1908 we have been able to give a field theoretical proof of the statement. We have also corrected an important erroneous interpretation in the previous version regarding the 2+1 effective action; Typo

Magnetic Catalysis in AdS4

We study the formation of fermion condensates in Anti de Sitter space. In particular, we describe a novel version of magnetic catalysis that arises for fermions in asymptotically AdS4 geometries which cap off in the infra-red with a hard wall. We show that the presence of a magnetic field induces a fermion condensate in the bulk that spontaneously breaks CP symmetry. From the perspective of the dual boundary theory, this corresponds to a strongly coupled version of magnetic catalysis in d=2+1.Comment: 22 pages, 4 figures. v2: References added, factors of 2 corrected, extra comments added in appendix. v3: extra comments about fermion modes in a hard wall background. v4: A final factor of

Structure and Computation in Immunoreagent Design : From Diagnostics to Vaccines

Novel immunological tools for efficient diagnosis and treatment of emerging infections are urgently required. Advances in the diagnostic and vaccine development fields are continuously progressing, with reverse vaccinology and structural vaccinology (SV) methods for antigen identification and structure-based antigen (re)design playing increasingly relevant roles. SV, in particular, is predicted to be the front-runner in the future development of diagnostics and vaccines targeting challenging diseases such as AIDS and cancer. We review state-of-the-art methodologies for structure-based epitope identification and antigen design, with specific applicative examples. We highlight the implications of such methods for the engineering of biomolecules with improved immunological properties, potential diagnostic and/or therapeutic uses, and discuss the perspectives of structure-based rational design for the production of advanced immunoreagents. Immunodiagnostic-based serological tests offer rapid and high-throughput diagnosis of multiple pathogens and can ascertain disease progression.3D structures of protein antigens can be used to predict epitope location using computational biology methods.Computationally designed synthetic epitopes can provide new chemical tools with distinct applications, from diagnosis and patient profiling to therapeutic approaches based on new vaccines.Structure-based antigen design is predicted to deliver future vaccines targeting challenging diseases such as HIV and cancer.As an alternative to nanoparticle epitope presentation systems, structure-based in silico epitope grafting and design methods may be adopted to transplant epitopes onto protein scaffolds to generate antigens that stimulate more potent immune responses

Small-Molecule Theranostic Probes: A Promising Future in Neurodegenerative Diseases

Prion diseases are fatal neurodegenerative illnesses, which include Creutzfeldt-Jakob disease in humans and scrapie, chronic wasting disease, and bovine spongiform encephalopathy in animals. They are caused by unconventional infectious agents consisting primarily of misfolded, aggregated, \u3b2 -sheet-rich isoforms, denoted prions, of the physiological cellular prion protein (PrP(C)). Many lines of evidence suggest that prions (PrP(Sc)) act both as a template for this conversion and as a neurotoxic agent causing neuronal dysfunction and cell death. As such, PrP(Sc) may be considered as both a neuropathological hallmark of the disease and a therapeutic target. Several diagnostic imaging probes have been developed to monitor cerebral amyloid lesions in patients with neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, and prion disease). Examples of these probes are Congo red, thioflavin T, and their derivatives. We synthesized a series of styryl derivatives, denoted theranostics, and studied their therapeutic and/or diagnostic potentials. Here we review the salient traits of these small molecules that are able to detect and modulate aggregated forms of several proteins involved in protein misfolding diseases. We then highlight the importance of further studies for their practical implications in therapy and diagnostics

Evolutionary Implications of Environmental Toxicant Exposure

Homo sapiens have been exposed to various toxins and harmful compounds that change according to various phases of human evolution. Population genetics studies showed that such exposures lead to adaptive genetic changes; while observing present exposures to different toxicants, the first molecular mechanism that confers plasticity is epigenetic remodeling and, in particular, DNA methylation variation, a molecular mechanism proposed for medium-term adaptation. A large amount of scientific literature from clinical and medical studies revealed the high impact of such exposure on human biology; thus, in this review, we examine and infer the impact that different environmental toxicants may have in shaping human evolution. We first describe how environmental toxicants shape natural human variation in terms of genetic and epigenetic diversity, and then we describe how DNA methylation may influence mutation rate and, thus, genetic variability. We describe the impact of these substances on biological fitness in terms of reproduction and survival, and in conclusion, we focus on their effect on brain evolution and physiology

Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?

The present review explores the role of xanthine oxidoreductase (XOR) in the development and progression of chronic kidney disease (CKD). Human XOR is a multi-level regulated enzyme, which has many physiological functions, but that is also implicated in several pathological processes. The main XOR activities are the purine catabolism, which generates uric acid, and the regulation of cell redox state and cell signaling, through the production of reactive oxygen species. XOR dysregulation may lead to hyperuricemia and oxidative stress, which could have a pathogenic role in the initial phases of CKD, by promoting cell injury, hypertension, chronic inflammation and metabolic derangements. Hypertension is common in CKD patients and many mechanisms inducing it (upregulation of renin-angiotensin-aldosterone system, endothelial dysfunction and atherosclerosis) may be influenced by XOR products. High XOR activity and hyperuricemia are also risk factors for obesity, insulin resistance, type 2 diabetes and metabolic syndrome that are frequent CKD causes. Moreover, CKD is common in patients with gout, which is characterized by hyperuricemia, and in patients with cardiovascular diseases, which are associated with hypertension, endothelial dysfunction and atherosclerosis. Although hyperuricemia is undoubtedly related to CKD, controversial findings have been hitherto reported in patients treated with urate-lowering therapies